Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.
At AMCP 2023, Michael Burger, senior consultant at Point-of-Care Partners, explained the important role real-time benefit check (RTBC) plays in the decision-making process.
What is real-time benefit check?
Real-time benefit check—also known as RTBC—is an electronic transaction, which is used to identify a patient's prescription benefit coverage and to identify what their out-of-pocket costs will be, as well as what any of the restrictions on that prescription might be, things like prior authorization. RTBC is available to the prescriber. So in the doctor's office at the point where the prescription is being written, information about what that prescription will cost the patient is available and it can be used as part of the decision making process to decide which drug to order for the patient.
How does RTBC encourage providers to consider costs when prescribing medications?
Prescription cost is something that is not especially transparent, it isn't uncommon for the patient to understand what the prescription will cost only when they get to the pharmacy counter. So sometimes that results in the patient not being able to afford the medication, or maybe being forced to pay for the medication and then not use it according to instructions. Maybe they cut a pill in half or they take it every other day.
So the idea behind RTBC is that the cost to the patient is known to the physician at the point where they're writing the prescription, so they can decide on the most cost effective drug, one that they know that the patient can afford, so that way they're sure that the patient gets on the therapy.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More